- #ASCO26: Bristol Myers details Phase 3 trial win for Pomalyst successorBristol Myers Squibb’s next-gen multiple myeloma drug cut the risk of disease progression or death for certain patients by 52% when added on top of a combination treatment regimen. The New Jersey…Endpoints · 1mo ago↗ source
- David Chang to hand over the reins at Allogene; Ex-Esperion CEO gets started at PhlowLongtime Allogene CEO David Chang will be stepping down at the end of June. Chang has served as the company’s CEO for the past eight years and will be succeeded by ...Endpoints · 1mo ago↗ source
- Pfizer strikes Innovent deal worth up to $10.5B for a dozen cancer programsOn the eve of this year’s ASCO annual meeting, Pfizer said it is teaming up with China’s Innovent Biologics to advance a portfolio of 12 early-stage antibody-drug conjugates and multi-specific anti…